The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma
Open accessAbstract
Objectives: To establish an evidence-based cut-off to differentiate between early and late recurrence and to compare clinicopathologic risk factors between the two groups. Summary Background Data: A clear definition of “early recurrence” after pancreatic ductal adenocarcinoma resection is currently lacking. Methods: Patients undergoing pancreatectomy for pancreatic ductal adenocarcinoma between 2000 and 2013 were included. Exclusion criteria were neoadjuvant therapy and incomplete follow-up. A minimum P-value approach was used to evaluate the optimal cut-off value of recurrence-free survival to divide the patients into early and late recurrence cohorts based on subsequent prognosis. Potential risk factors for early recurrence were assessed with logistic regression models. Results: Of 957 included patients, 204 (21.3%) were recurrence-free at last follow-up. The optimal length of recurrence-free survival to distinguish between early (n = 388, 51.5%) and late recurrence (n = 365, 48.5%) was 12 months (P < 0.001). Patients with early recurrence had 1-, and 2-year post-recurrence survival rates of 20 and 6% compared with 45 and 22% for the late recurrence group (both P < 0.001). Preoperative risk factors for early recurrence included a Charlson age-comorbidity index ≥4 (OR 1.65), tumor size > 3.0 cm on computed tomography (OR 1.53) and CA 19-9 > 210 U/mL (OR 2.30). Postoperative risk factors consisted of poor tumor differentiation grade (OR 1.66), microscopic lymphovascular invasion (OR 1.70), a lymph node ratio > 0.2 (OR 2.49), and CA 19-9 > 37 U/mL (OR 3.38). Adjuvant chemotherapy (OR 0.28) and chemoradiotherapy (OR 0.29) were associated with a reduced likelihood of early recurrence. Conclusion: A recurrence-free interval of 12 months is the optimal threshold for differentiating between early and late recurrence, based on subsequent prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
Recent progress in pancreatic cancer
Wolfgang, C. L., Herman, J. M., Laheru, D. A., Klein, A. P., Erdek, M. A., Fishman, E. K., & Hruban, R. H. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21190 · Cited by 910
Self-citationGroot, V. P., Rezaee, N., Wu, W., Cameron, J. L., Fishman, E. K., Hruban, R. H., Weiss, M. J., Zheng, L., Wolfgang, C. L., & He, J. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002234 · Cited by 757
Self-citationEvans, D. B., Varadhachary, G. R., Crane, C. H., Sun, C. C., Lee, J. E., Pisters, P. W. T., Vauthey, J.-N., Wang, H., Cleary, K. R., Staerkel, G. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8634 · Cited by 731
Cohen, J. D., Javed, A. A., Thoburn, C., Wong, F., Tie, J., Gibbs, P., Schmidt, C. M., Yip-Schneider, M. T., Allen, P. J., Schattner, M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704961114 · Cited by 582
Self-citationRadioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.
Del Villano, B. C., Brennan, S., Brock, P., Bucher, C., Liu, V, McClure, M., Rake, B., Space, S., Westrick, B., Schoemaker, H., et al. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.3.549 · Cited by 506
Berger, A. C., Garcia, M., Hoffman, J. P., Regine, W. F., Abrams, R. A., Safran, H., Konski, A., Benson, A. B., MacDonald, J., & Willett, C. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6288 · Cited by 371
Khorana, A. A., Mangu, P. B., Berlin, J., Engebretson, A., Hong, T. S., Maitra, A., Mohile, S. G., Mumber, M., Schulick, R., Shapiro, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5553 · Cited by 366
Cited by
Zhao, B., Cao, B., Xia, T., Zhu, L., Yu, Y., Lu, C., Tang, T., Wang, Y., & Ju, S. (2025) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29708 · Cited by 9
Metadata
- Authors
- Groot, V. P., Gemenetzis, G., Blair, A. B., Rivero-Soto, R. J., Yu, J., Javed, A. A., Burkhart, R. A., Rinkes, I. H. M. B., Molenaar, I. Q., Cameron, J. L., Weiss, M. J., Wolfgang, C. L., & He, J.
- Venue
- Annals of Surgery
- Published
- 2019-06
- Volume
- 269
- Issue
- 6
- Pages
- 1154-1162
- ISSN
- 0003-4932 (ISSN-L)
- 1528-1140
- OpenAlex
- W2801588121
- Cited by
- 373
- References
- 31
- FWCI
- 11.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. https://app.cochat.ai/papers/10.1097/sla.0000000000002734
- The paper
- Groot, V. P., Gemenetzis, G., Blair, A. B., Rivero-Soto, R. J., Yu, J., Javed, A. A., Burkhart, R. A., Rinkes, I. H. M. B., Molenaar, I. Q., Cameron, J. L., Weiss, M. J., Wolfgang, C. L., & He, J. (2019). Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Annals of Surgery. https://doi.org/10.1097/sla.0000000000002734
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.